SONN Stock: Price, Forecast, Financials & AI Analysis

Loading...

High

--

Open

--

VWAP

--

Vol

--

Mkt Cap

2.95M

Low

--

Amount

--

EV/EBITDA(TTM)

--

Total Shares

--

EV

8.60M

EV/OCF(TTM)

--

P/S(TTM)

3.42

Sonnet BioTherapeutics Holdings, Inc. is a clinical-stage, oncology-focused biotechnology company with a proprietary platform for biologic medicines of single-or bifunctional action. The Fully Human Albumin Binding (FHAB), a technology which utilizes a fully human single chain antibody fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its FHAB is designed to specifically target tumor and lymphatic tissue. The Company's lead program, SON-1010, or IL-12-FHAB, is in development for the treatment of solid tumors and ovarian cancer. SON-1010 is being evaluated in an ongoing Phase 1/2a study, in combination with atezolizumab (Tecentriq) for the treatment of platinum-resistant ovarian cancer (PROC). The Company is also evaluating its second program, SON-1210, an IL12-FHAB-IL15 for solid tumor. Its SON-080 program is a low dose of rhIL-6 in development for Chemotherapy-Induced Peripheral Neuropathy (CIPN) and Diabetic Peripheral Neuropathy (DPN).

Show More

Events Timeline

(ET)

2025-12-02

09:30:00

Sonnet BioTherapeutics Stockholders Approve Merger with Hyperliquid Strategies

2025-10-15 (ET)

2025-10-15

10:11:27

Sonnet BioTherapeutics and Spanios Partner for Non-Clinical Research on SON-1010

2025-08-11 (ET)

2025-08-11

09:19:44

Sonnet BioTherapeutics releases 'What This Means' investor segment

2025-08-04 (ET)

2025-08-04

08:46:26

Sonnet BioTherapeutics expands clinical evaluation of SON-1010 dose escalation

2025-07-14 (ET)

2025-07-14

06:03:04

Sonnet BioTherapeutics enters $888M business combination with Rorschach I

2025-04-04 (ET)

2025-04-04

09:04:16

Sonnet says SON-1010 demonstrates 'strong safety profile' in atezolizumab combo

2025-04-01 (ET)

2025-04-01

07:38:42

Sonnet BioTherapeutics announces passing of founder, CEO Pankaj Mohan

2025-03-26 (ET)

2025-03-26

09:08:22

Sonnet BioTherapeutics completes first safety review of SON-1010

2025-03-19 (ET)

2025-03-19

08:51:44

Sonnet BioTherapeutics receives notice of allowance for U.S. patent for IL-18

News

an image of Newsfilter

2025-12-02Newsfilter

Hyperliquid Completes Merger with Sonnet, Stock to Trade on Nasdaq

an image of Newsfilter

2025-12-02Newsfilter

Sonnet BioTherapeutics Shareholders Approve Merger with Hyperliquid Strategies Inc.

an image of Globenewswire

2025-12-02Globenewswire

Sonnet BioTherapeutics Secures Shareholder Approval for Merger with Hyperliquid Strategies

an image of NASDAQ.COM

2025-12-01NASDAQ.COM

Biotech Stocks Surge in After-Hours Trading with Gains from BioAtla, Entero, and Sonnet

an image of MarketWatch

2025-09-27MarketWatch

Numerous crypto-treasury firms are valued below their digital asset holdings.

an image of Newsfilter

2025-09-19Newsfilter

Sonnet to Showcase at the MedInvest Biotech & Pharma Conference

Valuation Metrics

The current forward P/E ratio for Sonnet Biotherapeutics Holdings Inc (SONN.O) is -0.36, compared to its 5-year average forward P/E of -0.61. For a more detailed relative valuation and DCF analysis to assess Sonnet Biotherapeutics Holdings Inc 's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

an image of dotted line Image

N/A

5Y Average PE

-0.61

Current PE

-0.36

Overvalued PE

-0.11

Undervalued PE

-1.10

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

an image of dotted line Image

N/A

5Y Average EV/EBITDA

-0.07

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.12

Undervalued EV/EBITDA

-0.27

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

an image of dotted line Image

N/A

5Y Average PS

81.50

Current PS

0.00

Overvalued PS

162.09

Undervalued PS

0.90

Financials

Al Analysis

Annual

Quarterly

Trading Trends

People Also Watch

Frequently Asked Questions

What is Sonnet Biotherapeutics Holdings Inc (SONN) stock price today?

The current price of SONN is 0 USD — it has increased 0 % in the last trading day.

What is Sonnet Biotherapeutics Holdings Inc (SONN)'s business?

Sonnet BioTherapeutics Holdings, Inc. is a clinical-stage, oncology-focused biotechnology company with a proprietary platform for biologic medicines of single-or bifunctional action. The Fully Human Albumin Binding (FHAB), a technology which utilizes a fully human single chain antibody fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its FHAB is designed to specifically target tumor and lymphatic tissue. The Company's lead program, SON-1010, or IL-12-FHAB, is in development for the treatment of solid tumors and ovarian cancer. SON-1010 is being evaluated in an ongoing Phase 1/2a study, in combination with atezolizumab (Tecentriq) for the treatment of platinum-resistant ovarian cancer (PROC). The Company is also evaluating its second program, SON-1210, an IL12-FHAB-IL15 for solid tumor. Its SON-080 program is a low dose of rhIL-6 in development for Chemotherapy-Induced Peripheral Neuropathy (CIPN) and Diabetic Peripheral Neuropathy (DPN).

What is the price predicton of SONN Stock?

Wall Street analysts forecast SONN stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for SONN is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Sonnet Biotherapeutics Holdings Inc (SONN)'s revenue for the last quarter?

Sonnet Biotherapeutics Holdings Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

What is Sonnet Biotherapeutics Holdings Inc (SONN)'s earnings per share (EPS) for the last quarter?

Sonnet Biotherapeutics Holdings Inc. EPS for the last quarter amounts to USD, decreased -100.00 % YoY.

How many employees does Sonnet Biotherapeutics Holdings Inc (SONN). have?

Sonnet Biotherapeutics Holdings Inc (SONN) has 13 emplpoyees as of January 17 2026.

What is Sonnet Biotherapeutics Holdings Inc (SONN) market cap?

Today SONN has the market capitalization of 2.95M USD.